GlassScriptPhysician profile
Michael F Demyen
NPI 1568611465
$6,230.51
in general payments reported to CMS, 2019-2025
41 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $224 · 2021: $785 · 2022: $461 · 2023: $479 · 2024: $1,271 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,973 · Education: $16.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,972.65 |
| Education | $16.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,208.54 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $979.32 | 2019-2025 | Linzess, Viberzi, Creon |
| Ardelyx, INC. | $455.36 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $440.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $417.40 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $379.10 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $356.07 | 2019-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $290.49 | 2025 | Voquezna |
| Novo Nordisk INC | $219.49 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $135.80 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $119.08 | 2024-2025 | Zenpep |
| Pfizer INC. | $119.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $110.85 | 2019-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.57 | 2021 | |
| Lilly USA, LLC | $78.58 | 2020-2025 | Zepbound |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $77.22 | 2019-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $61.79 | 2020-2024 | Rebyota |
| Redhill Biopharma INC. | $51.22 | 2020-2022 | |
| Genzyme Corporation | $50.81 | 2024-2025 | |
| Celgene Corporation | $49.58 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $48.68 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $45.10 | 2019-2021 | |
| Amarin Pharma, INC. | $41.75 | 2021 | |
| Amgen INC. | $41.68 | 2020-2023 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $41.53 | 2022 | |
| Abbott Laboratories | $37.95 | 2024 | Freestyle Libre 3, Freestyle Libre |
| Intercept Pharmaceuticals, INC. | $27.09 | 2019-2022 | |
| Eisai INC. | $26.05 | 2021 | |
| Gilead Sciences, INC. | $25.77 | 2019 | |
| Allergan, INC. | $24.98 | 2019 | |
| Exact Sciences Corporation | $19.53 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $19.19 | 2024 | Cimzia |
| Teva Pharmaceuticals USA, INC. | $18.64 | 2022 | |
| Radius Health, INC. | $17.00 | 2025 | Tymlos |
| Celltrion USA INC. | $16.05 | 2024 | Zymfentra |
| Mannkind Corporation | $15.28 | 2022 | |
| Daiichi Sankyo INC. | $14.96 | 2019 | |
| Dexcom, INC. | $14.28 | 2021 | |
| Alfasigma USA, INC. | $13.91 | 2020 | |
| Olympus America INC. | $13.58 | 2025 | Hanarostent Esophagus Tts(Ccc) |
| Echosens North America, INC. | $8.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Demyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.